dc.contributor.author | Bélanger, Jean-Christophe | |
dc.contributor.author | Bouchard, Véronique | |
dc.contributor.author | Le Blanc, Jessica | |
dc.contributor.author | Starnino, Louisia | |
dc.contributor.author | Welman, Mélanie | |
dc.contributor.author | Chabot-Blanchet, Malorie | |
dc.contributor.author | Busseuil, David | |
dc.contributor.author | Chertkow, Howard | |
dc.contributor.author | D'Antono, Bianca | |
dc.contributor.author | Lordkipanidzé, Marie | |
dc.date.accessioned | 2021-09-22T18:51:52Z | |
dc.date.available | NO_RESTRICTION | fr |
dc.date.available | 2021-09-22T18:51:52Z | |
dc.date.issued | 2021-09-07 | |
dc.identifier.uri | http://hdl.handle.net/1866/25741 | |
dc.publisher | Frontiers media | fr |
dc.rights | Ce document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License. | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | Platelets | fr |
dc.subject | BDNF | fr |
dc.subject | Coronary artery disease | fr |
dc.subject | Cognitive impairment | fr |
dc.subject | Mediation model | fr |
dc.title | Brain-derived neurotrophic factor mitigates the association between platelet dysfunction and cognitive impairment | fr |
dc.type | Article | fr |
dc.contributor.affiliation | Université de Montréal. Faculté des arts et des sciences. Département de psychologie | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de pharmacie | fr |
dc.identifier.doi | 10.3389/fcvm.2021.739045 | |
dcterms.abstract | Background: Platelet hyperactivity is deleterious in coronary artery disease (CAD),
requiring lifelong antiplatelet therapy, and is associated with worse cognitive outcomes.
Upon activation, platelets release Brain-Derived Neurotrophic Factor (BDNF), a
neurotrophin protective against cognitive decline. Given these apparently opposing
effects of platelet activation on cognitive health, we investigated whether BDNF levels
intercede in the relationship between platelet activation and cognitive function; and
whether this relationship is moderated by the presence of CAD.
Methods: In this cross-sectional study, 1,280 participants with (n = 673) and without
CAD (n = 607) completed the Montreal Cognitive Assessment (MoCA). Plasma BDNF
and soluble P-selectin (a marker of platelet activity) levels were assessed using multiplex
flow cytometry.
Results: In a mediation model, platelet activity was correlated with higher plasma
BDNF concentrations (b = 0.53, p < 0.0001). The relationship between sP-selectin
and BDNF concentrations was stronger for individuals without CAD (b = 0.71, p <
0.0001) than for CAD participants (b = 0.43, p < 0.0001; pinteraction < 0.0001). Higher
BDNF concentrations were associated with higher MoCA scores (b = 0.26, p = 0.03).
The overall effect of platelet activity on cognitive performance was non-significant (total
effect: b = −0.12, p = 0.13), and became significant when accounting for BDNF as a
mediating factor (direct effect: b = −0.26, p = 0.01). This resulted in a positive indirect
effect of platelet activity (via BDNF) on MoCA scores (b = 0.14, CI 95% 0.02–0.30), that
was smaller in CAD participants than in non-CAD participants [1 −0.07 (95% CI −0.14
to −0.01)].
Conclusions: BDNF released from activated platelets could be a mitigating factor in a
negative association between platelet activity and cognitive function. | fr |
dcterms.isPartOf | urn:ISSN:2297-055X | fr |
dcterms.language | eng | fr |
UdeM.ReferenceFournieParDeposant | https://www.frontiersin.org/articles/10.3389/fcvm.2021.739045/full | fr |
UdeM.VersionRioxx | Version publiée / Version of Record | fr |
oaire.citationTitle | Frontiers in cardiovascular medicine | fr |
oaire.citationVolume | 8 | fr |